Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...
Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company developing a nanomedicine therapeutic that traverses the blood ...
Panelists discuss how aflibercept 8 mg maintains a safety profile similar to 2 mg and how workflow, systemic risk, and ...
Clinical Trials in Cancer Cachexia, Inflammatory Bowel Disease and Retinal Disorders are Planned MONTVALE, N. J., Jan. 07, 2026 (GLOBE ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...
Its distinctive occlusive texture is closer to a balm, which according to reviewers, can be more hydrating compared to other ...
LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of ...
Morning Overview on MSN
Researchers think they’ve found a path to restoring human vision
For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...
Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets - - Pivotal Phase 3 trials in wet AMD on track for data readout beginning in mid-2026 ...
Eli Lilly ramps up M&A activity, adding Ventyx and other assets to diversify beyond obesity as competition in the GLP-1 space ...
Multiple milestones anticipated from late-stage portfolio including topline results from DIAMOND Phase 3 trials with OCS-01 ...
Driving with poor eyesight or an untreated eye condition can be deadly. Currently, drivers are expected to self-report any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback